The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas
Francis D, Dougan J, Pillsbury C, Park S, Langermann S, Koff J, Li Z, Flowers C, Porter C. The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas. Blood 2023, 142: 4367. DOI: 10.1182/blood-2023-190405.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaAggressive B-cell lymphomasGerminal center B cellsImmune responseBurkitt's lymphomaLymphoma casesDisease progressionSiglec-15Immune deficient (SCID) BALB/c miceR diffuse large B-cell lymphomaB cellsDeficient BALB/c miceLocal anti-tumour immune responseAggressive mature B-cell lymphomaAnti-tumor immune responseBALB/c miceLarge B-cell lymphomaHealthy donor PBMCsIntensive salvage regimensMost diffuse large B-cell lymphomasEvent-free survivalFirst-line treatmentRefractory hematologic malignanciesNon-Hodgkin lymphoma cases